
    
      Primary target: determine the safety of introducing CD 34+ autologous progenitor cells
      (centrally grafted or mobilized in peripheral blood) in the myocardium of ischemic cardiac
      disease patients. Secondary target: determine clinical effects of grafted cells on remodeling
      pathology.
    
  